ORIC Pharmaceuticals to Attend Investor Conferences
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) is a clinical-stage oncology company dedicated to developing innovative treatments that address therapeutic resistance. The management team has announced their participation in several key investor conferences taking place in September.
Upcoming Conference Details
One of the major events ORIC Pharmaceuticals will attend is the 2024 Wells Fargo Healthcare Conference. Management will participate in a fireside chat on Thursday, September 5, starting at 8:00 a.m. ET. This discussion will provide valuable insights into the company’s strategic objectives and innovations.
Next, ORIC will also be featured at the Baird 2024 Global Healthcare Conference on Tuesday, September 10. Another fireside chat is scheduled for 10:50 a.m. ET, and access to this session is limited to conference attendees.
Finally, ORIC will participate in the 2024 Cantor Global Healthcare Conference, with a fireside chat planned for Thursday, September 19 at 8:35 a.m. ET. These events present essential opportunities for ORIC to connect with potential investors and share updates on their clinical program advancements.
Webcasts and Replay Availability
After the events, live webcasts of the discussions from both the Wells Fargo and Cantor conferences will be made available. Interested individuals can find these webcasts in the investor section of ORIC's official website. Additionally, replays will be accessible for 90 days following the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is committed to improving patients’ lives by Overcoming Resistance In Cancer. Their pipeline includes several promising clinical-stage product candidates aimed at addressing critical challenges in cancer treatment resistance.
Overview of Current Pipeline
Among their leading candidates is ORIC-114, a powerful brain-penetrant inhibitor that selectively targets EGFR and HER2, with a focus on exon 20 insertion mutations across various genetically defined cancers. This innovative therapy is gaining traction in the oncology field.
Another important candidate is ORIC-944, an allosteric inhibitor aimed at the polycomb repressive complex 2 (PRC2) through the EED subunit, designed specifically for prostate cancer treatment. ORIC-533 also shows promise as an orally bioavailable small molecule inhibitor of CD73, which plays a crucial role in the adenosine pathway linked to resistance against chemotherapy and immunotherapy, particularly in multiple myeloma.
In addition to these products, ORIC® is actively developing multiple precision medicines that target various hallmark mechanisms of resistance in cancer therapies.
Company Locations
ORIC Pharmaceuticals has offices in South San Francisco and San Diego, California, strategically positioning the company within key biopharmaceutical hubs.
Contact Information
For more information about ORIC Pharmaceuticals, interested parties can visit their website or reach out to:
Dominic Piscitelli, Chief Financial Officer
Email: dominic.piscitelli@oricpharma.com
Email: info@oricpharma.com
Frequently Asked Questions
What is ORIC Pharmaceuticals known for?
ORIC Pharmaceuticals focuses on developing innovative therapies that target mechanisms of resistance in cancer treatment.
When is ORIC participating in the upcoming investor conferences?
ORIC will attend investor conferences throughout September, specifically on the 5th, 10th, and 19th.
How can I access the webcasts of ORIC's investor conferences?
The webcasts will be available through the investor section of ORIC's official website, with replays accessible for 90 days after the events.
What are the key product candidates in ORIC's pipeline?
Key product candidates in ORIC's pipeline include ORIC-114, ORIC-944, and ORIC-533, each targeting specific mechanisms of resistance related to cancer.
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals operates offices in South San Francisco and San Diego, California, enhancing their presence in prominent biopharmaceutical markets.
